NCT00565851

Who might be able to join this trial:

• You have been diagnosed with a recurrent (come-back) cancer of the ovaries, the lining of the abdomen (peritoneal), or the fallopian tubes, confirmed by a tissue sample.
• Your cancer is one of these specific types: serous, endometrioid, mucinous, undifferentiated, clear cell, mixed epithelial, transitional cell, malignant Brenner's tumor, or adenocarcinoma (not otherwise specified).
• You had a complete response (cancer fully went away) after your first round of chemotherapy using platinum and taxane drugs (at least 3 cycles).
• After finishing your first chemotherapy, your physical exam, pelvic exam, and CA-125 blood test all came back normal, and any scans taken afterwards showed no signs of disease.
• You had at least 6 months free of cancer symptoms after finishing your first chemotherapy before your cancer came back.
• If you received maintenance (ongoing) chemotherapy after your first treatment, it must have been stopped for at least 6 months before your cancer came back; if you received a biological or hormonal maintenance therapy, your cancer must have come back more than 6 months after finishing chemotherapy, and at least 4 weeks after your last biological therapy dose.
• Your returning cancer must be clearly visible or detectable at the time of joining the study.
• Your cancer must be measurable on scans — at least one tumor spot that is 20mm or larger (or 10mm or larger on a special spiral CT scan).
• Your blood counts and organ function must be within acceptable ranges, including: enough white blood cells (infection-fighting cells), enough platelets (clotting cells), healthy kidney function, healthy liver function, and normal bilirubin levels.
• If you joined before August 29, 2011, or plan to receive a drug called bevacizumab, your urine protein levels must be within an acceptable range (confirm with trial site).
• If you are not a candidate for surgery to reduce the tumor, you may still be eligible for the chemotherapy part of the trial (confirm with trial site).
• You must be well enough to carry out normal daily activities or light work (performance status 0, 1, or 2 on the GOG scale).
• You must sign a consent form agreeing to take part and allowing your health information to be used.

Who may not be able to join:

• You have had more than one previous course of chemotherapy (maintenance therapy on its own does not count as a second course).
• You are currently receiving immunotherapy or radiation therapy.
• You have previously had radiation treatment to any part of your abdomen or pelvis.
• You have already had surgery to reduce your recurring tumor.
• You need IV fluids or nutrition and have signs of a partial bowel blockage or bowel perforation (hole).
• You have previously received chemotherapy for a different cancer in the abdomen or pelvis (other than ovarian, fallopian tube, or peritoneal cancer).
• You have or have had uterine (endometrial) cancer, unless it was a very early-stage, low-risk cancer meeting specific conditions (confirm with trial site).
• You have an infection that is not under control.
• You have serious health problems unrelated to your cancer that could prevent you from safely completing the study.
• You have moderate or severe nerve damage (numbness, tingling, or pain) in your hands or feet (grade 2 or higher).
• You have had a serious allergic reaction to carboplatin, paclitaxel, or similar drugs — unless you were successfully treated again using a special desensitization program.
• If receiving bevacizumab: you have a known allergy to certain laboratory-made antibody products (confirm with trial site).
• You are pregnant, breastfeeding, or of childbearing age and not using adequate birth control.
• You have had another serious (invasive) cancer in the past 5 years, other than certain non-melanoma skin cancers, or if a previous cancer treatment would make this trial unsafe for you.
• If receiving bevacizumab: you have active bleeding, a bleeding disorder, or a condition with a high risk of serious bleeding.
• If receiving bevacizumab: you have a brain tumor, uncontrolled seizures, cancer that has spread to the brain, or a stroke within the past 5 years.